© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Clinuvel Pharmaceuticals Limited (CLVLY) stock remained unchanged at $7.36 a share on OTC. The stock opened at $6.98, fluctuating between $6.98 to $7.40 during the session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jun 17, 2026 | 6.98 | 7.40 | 6.98 | 7.36 | 5.31K |
| Jun 16, 2026 | 7.15 | 7.25 | 6.85 | 6.92 | 11.31K |
| Jun 15, 2026 | 6.25 | 6.94 | 6.25 | 6.94 | 3.96K |
| Jun 12, 2026 | 6.62 | 6.62 | 6.26 | 6.26 | 429 |
| Jun 11, 2026 | 6.20 | 6.20 | 6.20 | 6.20 | 566 |
| Jun 10, 2026 | 6.34 | 6.34 | 6.19 | 6.19 | 1.3K |
| Jun 09, 2026 | 6.50 | 6.50 | 6.36 | 6.36 | 3.31K |
| Jun 08, 2026 | 6.60 | 6.73 | 6.59 | 6.73 | 1.82K |
| Jun 05, 2026 | 6.67 | 6.67 | 6.50 | 6.60 | 1.36K |
| Jun 04, 2026 | 6.55 | 6.55 | 6.37 | 6.37 | 2K |
| Jun 03, 2026 | 6.40 | 6.40 | 6.40 | 6.40 | 515 |
| Jun 01, 2026 | 6.75 | 6.95 | 6.75 | 6.95 | 2.6K |
| May 29, 2026 | 6.74 | 7.09 | 6.68 | 6.68 | 1.01K |
| May 27, 2026 | 6.33 | 6.56 | 6.33 | 6.56 | 4.09K |
| May 26, 2026 | 6.90 | 6.90 | 6.90 | 6.90 | 173 |
| May 22, 2026 | 6.53 | 6.53 | 6.40 | 6.40 | 1.31K |
| May 21, 2026 | 6.75 | 6.75 | 6.75 | 6.75 | 1.06K |
| May 20, 2026 | 6.92 | 6.92 | 6.92 | 6.92 | 7 |
| May 19, 2026 | 5.98 | 6.62 | 5.98 | 6.62 | 406 |
| May 15, 2026 | 6.84 | 6.84 | 6.84 | 6.84 | 678 |
Clinuvel Pharmaceuticals Limited is a biopharmaceutical firm dedicated to creating and marketing therapies for individuals worldwide grappling with genetic, metabolic, and severe medical conditions, operating across Australia, Europe, the United States, and Switzerland. Their flagship therapeutic, SCENESSE, is a systemic photoprotective medication designed to shield adult patients suffering from erythropoietic protoporphyria (EPP) from light-induced damage. The company's development portfolio also features CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which stimulates extended cellular activity; and PRÉNUMBRA, an injectable liquid form of afamelanotide. Clinuvel Pharmaceuticals has forged a partnership with HK Winhealth Pharma Group Co. Limited to deliver SCENESSE to EPP patients in the People's Republic of China through a specialized named patient program. Established in 1987, the company maintains its principal office in Melbourne, Australia.
| Employees | 100 |
| Beta | 0.61 |
| Sales or Revenue | $95.02M |
| 5Y Sales Change% | 1.87% |
| Fiscal Year Ends | June |
| Sector | Healthcare |
| Industry | Biotechnology |